Learn About Alpha-1 Antitrypsin Deficiency (AATD)

What is the definition of Alpha-1 Antitrypsin Deficiency (AATD)?

Alpha-1 antitrypsin (AAT) deficiency is a condition in which the body does not make enough of AAT, a protein that protects the lungs and liver from damage. The condition can lead to chronic obstructive pulmonary disease (COPD) and liver disease (cirrhosis).

What are the alternative names for Alpha-1 Antitrypsin Deficiency (AATD)?

AAT deficiency; Alpha-1 protease deficiency; COPD - alpha-1 antitrypsin deficiency; Cirrhosis - alpha-1 antitrypsin deficiency

What are the causes of Alpha-1 Antitrypsin Deficiency (AATD)?

AAT is a type of protein called a protease inhibitor. AAT is made in the liver and it works to protect the lungs and liver.

AAT deficiency means there is not enough of this protein in the body. It is caused by a genetic defect. The condition is most common among Europeans and North Americans of European descent.

Adults with severe AAT deficiency will develop emphysema, sometimes before 40 years of age. Smoking can increase the risk for emphysema and make it occur earlier.

What are the symptoms of Alpha-1 Antitrypsin Deficiency (AATD)?

Symptoms may include any of the following:

  • Shortness of breath with and without exertion, and other symptoms of COPD
  • Symptoms of liver failure
  • Loss of weight without trying
  • Wheezing
  • Coughing
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Alpha-1 Antitrypsin Deficiency (AATD)?

Treatment for AAT deficiency involves replacing the missing AAT protein. The protein is given through a vein each week or every 4 weeks. This is only slightly effective at preventing more lung damage in people without end-stage disease. This procedure is called augmentation therapy.

If you smoke, you need to quit.

Other treatments are also used for COPD and cirrhosis.

Lung transplant can be used for severe lung disease, and liver transplant can be used for severe cirrhosis.

Who are the top Alpha-1 Antitrypsin Deficiency (AATD) Local Doctors?
Internal Medicine
Internal Medicine
1775 Ballard Rd, 
Park Ridge, IL 
 (4.8 mi)
Languages Spoken:
English

Michael O'brien is an Internal Medicine provider in Park Ridge, Illinois. Dr. O'brien and is rated as an Advanced provider by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). His top areas of expertise are Emphysema, Subcutaneous Emphysema, Alpha-1 Antitrypsin Deficiency (AATD), and Chronic Obstructive Pulmonary Disease (COPD).

Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine

Respiratory Critical Care And Sleep Specialists LLC

1400 E Golf Rd, Suite 201, 
Des Plaines, IL 
 (2.6 mi)
Languages Spoken:
English, Hindi, Punjabi, Russian
Accepting New Patients
Offers Telehealth

Mukesh Ahluwalia is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Des Plaines, Illinois. Dr. Ahluwalia and is rated as an Experienced provider by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Pneumonia, Pleural Effusion, and Advanced Bronchoscopy. Dr. Ahluwalia is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Geriatrics | Family Medicine
Geriatrics | Family Medicine
1100 W Central Rd, Suite 301, 
Arlington Heights, IL 
 (3.0 mi)
Experience:
43+ years
Languages Spoken:
English, Filipino, Mandarin
Accepting New Patients

Michael Lim is a Geriatrics specialist and a Family Medicine provider in Arlington Heights, Illinois. Dr. Lim has been practicing medicine for over 43 years and is rated as an Experienced provider by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). His top areas of expertise are Atrial Fibrillation, Chronic Kidney Disease, End-Stage Renal Disease (ESRD), High Cholesterol, and Coronary Artery Bypass Graft (CABG). Dr. Lim is currently accepting new patients.

What is the outlook (prognosis) for Alpha-1 Antitrypsin Deficiency (AATD)?

Some people with this deficiency will not develop liver or lung disease. If you quit smoking, you can slow the progression of the lung disease.

COPD and cirrhosis can be life threatening.

What are the possible complications of Alpha-1 Antitrypsin Deficiency (AATD)?

Complications of AAT deficiency include:

  • Bronchiectasis (damage of the large airways)
  • COPD
  • Liver failure or cancer
When should I contact a medical professional for Alpha-1 Antitrypsin Deficiency (AATD)?

Contact your provider if you develop symptoms of AAT deficiency.

What are the latest Alpha-1 Antitrypsin Deficiency (AATD) Clinical Trials?
Universal Genomic Newborn Screening in the Wallonia-Brussels Federation: Baby Detect

Summary: Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions. With a simple blood test, rare genetic conditions can be easily detected, and the early start of transformative treatment will help avoid severe disabilities and increase the quality of life. Baby Detect Project is an innovative NBS program using a pane...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Prospective Phase 3 Multi-center 2-Year Placebo Controlled Double Blind Study to Evaluate the Efficacy and Safety of Kamada-AAT for Inhalation 80 Mg/Day in Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation Followed by a 2-Year Open Label Extension

Summary: The goal of this clinical trial is to learn if AAT for inhalation, at a dose of 80 mg/day can slow the progression of lung disease in people who have lung disease caused by severe genetic deficiency in Alpha 1 Antitrypsin (AATD). The main question it aims to answer is: • Can daily treatment with Kamada AAT for inhalation at a dose of 80 mg/day prevent or slow lung function worsening ? Lung functio...

Who are the sources who wrote this article ?

Published Date: July 31, 2022
Published By: Denis Hadjiliadis, MD, MHS, Paul F. Harron, Jr. Professor of Medicine, Pulmonary, Allergy, and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

What are the references for this article ?

Han MK, Lazarus SC. COPD: diagnosis and management. In: Broaddus VC, Ernst JD, King TE, et al, eds. Murray and Nadel's Textbook of Respiratory Medicine. 7th ed. Philadelphia, PA: Elsevier; 2022:chap 64.

Hatipoglu U, Stoller JK. a1 -antitrypsin deficiency. Clin Chest Med. 2016;37(3):487-504. PMID: 27514595 pubmed.ncbi.nlm.nih.gov/27514595/.

Winnie GB, Boas SR. a1 -antitrypsin deficiency and emphysema. In: Kliegman RM, St. Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Elsevier; 2020:chap 421.